Beamr video compression achieves up to 50% improvement for AVs
Lyell Immunopharma (NASDAQ:LYEL) President and CEO Lynn Seely sold a total of 797 shares of common stock on August 11 and 12, 2025. The sales, which covered tax withholding obligations from vested restricted stock units, amounted to $8,312. The transaction comes as the company’s stock shows strong momentum, with a notable return over the last three months, though still trading 67% below its 52-week high of $32.40. According to InvestingPro analysis, LYEL appears undervalued at current levels.
On August 11, Seely sold 391 shares at a weighted average price of $10.526, with prices ranging from $10.045 to $11.00. Following this transaction, Seely directly owns 35,234 shares.
The following day, August 12, Seely sold 406 shares at a weighted average price of $10.338, with prices ranging from $10.120 to $10.415. This sale left Seely with 34,828 shares.
In other recent news, Lyell Immunopharma has announced a significant private placement agreement that could raise up to $100 million. The company plans an initial closing of approximately $50 million in common stock, priced at $13.32 per share, with the transaction expected to close around July 25, 2025, pending customary conditions. Additionally, Lyell Immunopharma’s LYL314 therapy has shown promising results in a clinical trial. The therapy achieved an 88% overall response rate and a 72% complete response rate in patients with large B-cell lymphoma treated in the third- or later-line setting. Notably, 71% of patients who reached a complete response maintained it for at least six months. These developments highlight Lyell’s ongoing efforts in advancing cancer therapies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.